1 |
Boschi A, Uccelli L, Marvelli L, Cittanti C, Giganti M, Martini P. Technetium-99m Radiopharmaceuticals for Ideal Myocardial Perfusion Imaging: Lost and Found Opportunities. Molecules 2022;27:1188. [PMID: 35208982 DOI: 10.3390/molecules27041188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
2 |
Hu J, Li H, Sui Y, Du J. Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging 2021. [PMID: 34767047 DOI: 10.1007/s00259-021-05615-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
3 |
Duatti A. Review on 99mTc radiopharmaceuticals with emphasis on new advancements. Nucl Med Biol 2021;92:202-16. [PMID: 32475681 DOI: 10.1016/j.nucmedbio.2020.05.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 11.7] [Reference Citation Analysis]
|
4 |
Xi XY, Wang L, Hsu B, Zhao ZQ, Liu S, Fang W. 99mTc-3SPboroxime: A neutral 99mTc(III) radiotracer with high heart uptake and long myocardial retention. J Nucl Cardiol 2020. [PMID: 32180138 DOI: 10.1007/s12350-020-02087-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
MacPherson DS, Fung K, Cook BE, Francesconi LC, Zeglis BM. A brief overview of metal complexes as nuclear imaging agents. Dalton Trans 2019;48:14547-65. [PMID: 31556418 DOI: 10.1039/c9dt03039e] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
6 |
Fang W, Liu S. New 99mTc Radiotracers for Myocardial Perfusion Imaging by SPECT. Curr Radiopharm 2019;12:171-86. [PMID: 30727939 DOI: 10.2174/1874471012666190206102214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|